Morgan Stanley
PAND

Morgan Stanley’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Morgan Stanley’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,220
Closed -$974K – 8000
2021
Q1 		$974K Sell
16,220
-23,523
-59% -$852K ﹤0.01% 4745
2020
Q4 		$590K Buy
39,743
+28,369
+249% +$395K ﹤0.01% 4974
2020
Q3 		$130K Buy
+11,374
New +$194K ﹤0.01% 5305

Morgan Stanley's PAND Position: Q2 2021 in Review

Morgan Stanley sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 16,220 shares — an estimated $974K sold.

Morgan Stanley first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $974K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • Morgan Stanley reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Morgan Stanley sold 16,220 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $974K.
  • Morgan Stanley first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Morgan Stanley's Pandion Therapeutics Inc. Common Stock position peaked at $974K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Morgan Stanley's 13F filing for Q2 2021, filed 16 Aug 2021.